Imara Inc. is a clinical-stage biotechnology company dedicated to developing and commercializing novel therapeutics to treat patients suffering from rare inherited genetic disorders of hemoglobin, known as hemoglobinopathies. Our pipeline is built on the differentiated therapeutic potential of our lead product candidate, IMR-687, an oral, once-daily, potentially disease-modifying treatment in clinical development for sickle cell disease (SCD) and β-thalassemia. IMR-687 is uniquely designed as a highly selective, potent small molecule inhibitor of PDE9 with a multimodal mechanism that acts on red blood cells, white blood cells, adhesion mediators and other cell types. Our goal is to leverage the differentiated mechanism of action, ease of administration and stable drug properties of IMR-687 to potentially serve a broad range of patients suffering from hemoglobinopathies around the world, including those in underserved regions.